NEW OPPORTUNITIES IN TREATMENT OF SEVERE SYSTEMIC TYPE OF JUVENILE ARTHRITIS

<em>The article presents a case report of a severe clinical course of systemic type of juvenile arthritis, resistant to treatment with corticosteroids and classic immunosuppressive agents in girl 9 years old. Biological agent — tocilizumab showed beneficial effect: exudative lesions of joints,...

Full description

Bibliographic Details
Main Authors: R.V. Denisova, E.I. Alexeeva, A.O. Lisitsin, S.I. Valieva, T.M. Bzarova
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2010-01-01
Series:Вопросы современной педиатрии
Online Access:http://vsp.spr-journal.ru:80/jour/article/view/937
Description
Summary:<em>The article presents a case report of a severe clinical course of systemic type of juvenile arthritis, resistant to treatment with corticosteroids and classic immunosuppressive agents in girl 9 years old. Biological agent — tocilizumab showed beneficial effect: exudative lesions of joints, morning joint stiffness stopped and the range of motions restored in almost all affected joints in 8 weeks of treatment. A girl became more active, her emotional state improved. Laboratory signs of disease’s activity (ESR, concentration of C-reactive protein in plasma) were normalized in 4 weeks. The drug induced development of clinical and laboratory remission of a disease.</em><br /><strong><em>Key words: children, juvenile arthritis, treatment, tocilizumab.</em></strong><br /><span style="text-decoration: underline;"><em>(<em><em>Voprosy sovremennoi pediatrii — </em></em>Current Pediatrics. – 2010;9(4):<em><span>160-167</span></em>)</em></span>
ISSN:1682-5527
1682-5535